- Home
- EBS vs ALEC Comparison
EBS vs ALEC Comparison
Compare EBS & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- ALEC
- Stock Information
- Founded
- EBS 1998
- ALEC 2013
- Country
- EBS United States
- ALEC United States
- Employees
- EBS N/A
- ALEC N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBS Health Care
- ALEC Health Care
- Exchange
- EBS Nasdaq
- ALEC Nasdaq
- Market Cap
- EBS 459.6M
- ALEC 454.5M
- IPO Year
- EBS 2006
- ALEC 2019
- Fundamental
- Price
- EBS $9.40
- ALEC $3.76
- Analyst Decision
- EBS Strong Buy
- ALEC Strong Buy
- Analyst Count
- EBS 2
- ALEC 5
- Target Price
- EBS $14.00
- ALEC $20.67
- AVG Volume (30 Days)
- EBS 1.6M
- ALEC 749.0K
- Earning Date
- EBS 11-06-2024
- ALEC 11-06-2024
- Dividend Yield
- EBS N/A
- ALEC N/A
- EPS Growth
- EBS N/A
- ALEC N/A
- EPS
- EBS N/A
- ALEC N/A
- Revenue
- EBS $1,125,500,000.00
- ALEC $61,508,000.00
- Revenue This Year
- EBS $7.98
- ALEC N/A
- Revenue Next Year
- EBS $6.62
- ALEC $118.87
- P/E Ratio
- EBS N/A
- ALEC N/A
- Revenue Growth
- EBS 2.05
- ALEC N/A
- 52 Week Low
- EBS $1.42
- ALEC $3.49
- 52 Week High
- EBS $15.10
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- EBS 50.73
- ALEC 35.09
- Support Level
- EBS $8.12
- ALEC $3.57
- Resistance Level
- EBS $12.68
- ALEC $6.14
- Average True Range (ATR)
- EBS 0.91
- ALEC 0.48
- MACD
- EBS -0.18
- ALEC -0.20
- Stochastic Oscillator
- EBS 33.67
- ALEC 10.19
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.